Maintenance of Clinical Response With Continued Risankizumab Treatment for Moderate-to-Severe Psoriasis Through 304 Weeks: Interim Analysis of the LIMMitless Open-Label Extension Study. J of Skin [Internet]. 2023 Nov. 13 [cited 2026 May 22];7(6):s258. Available from: https://skin.dermsquared.com/skin/article/view/2428